Group One Trading
CCCC icon

Group One Trading’s C4 Therapeutics CCCC Stock Holding History

Group One Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
+21,773
New +$74.5K ﹤0.01% 4838
2026
Q1 		– Sell
-38,994
Closed -$91.8K – 7720
2025
Q4 		$74.5K Buy
38,994
+26,562
+214% +$62.9K ﹤0.01% 5251
2025
Q3 		$27.6K Buy
12,432
+12,417
+82,780% +$29.8K ﹤0.01% 6437
2025
Q2 		$21 Buy
+15
New +$22 ﹤0.01% 7817
2025
Q1 		– Sell
-32,883
Closed -$98.1K – 7646
2024
Q4 		$118K Buy
+32,883
New +$164K ﹤0.01% 4374
2024
Q3 		– Sell
-1,735
Closed -$10.4K – 6697
2024
Q2 		$8.02K Buy
+1,735
New +$10.3K ﹤0.01% 5740
2022
Q2 		– Sell
-4,500
Closed -$39.6K – 7858
2022
Q1 		$109K Buy
4,500
+4,000
+800% +$97.1K ﹤0.01% 5404
2021
Q4 		$16K Buy
500
+200
+67% +$7.91K ﹤0.01% 7096
2021
Q3 		$13K Buy
+300
New +$12.8K ﹤0.01% 7375

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Group One Trading's CCCC Position: Q2 2026 in Review

Group One Trading opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 21,773 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #4838 among its holdings. This is a return to the name: Group One Trading previously reported a position in CCCC as recently as Q4 2025.

Group One Trading first reported a position in CCCC in Q3 2021 and has held it in 9 quarters since. The position peaked at $118K in Q4 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Group One Trading held 21,773 shares of C4 Therapeutics worth $102K as of Q2 2026.
  • C4 Therapeutics was a new Group One Trading position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #4838 holding.
  • Group One Trading first reported a position in C4 Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • Group One Trading's C4 Therapeutics position peaked at $118K in Q4 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.